A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs - EXCEED

Study identifier:D5551R00015

ClinicalTrials.gov identifier:NCT05663515

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs

Medical condition

Pancreatic Cancer

Phase

N/A

Healthy volunteers

No

Study drug

Exenatide, Non-GLP-1 RA based glucose lowering drugs

Sex

All

Estimated Enrollment

24000

Study type

Observational

Age

18 Years - 99 Years

Date

Study Start Date: 30 Sept 2024
Estimated Primary Completion Date: 02 Mar 2026
Estimated Study Completion Date: 02 Mar 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA Ltd

Inclusion and exclusion criteria